warfarin and Hemangioendothelioma

warfarin has been researched along with Hemangioendothelioma* in 1 studies

Other Studies

1 other study(ies) available for warfarin and Hemangioendothelioma

ArticleYear
Reactive angioendotheliomatosis associated with antiphospholipid syndrome.
    Dermatology online journal, 2021, Mar-15, Volume: 27, Issue:3

    Reactive angioendotheliomatosis (RAE) is an uncommon, benign, antiproliferative condition associated with systemic diseases that may cause occlusion or inflammation of the vascular lumina. A link between antiphospholipid syndrome (APS) and RAE has been reported a few times in the literature. Herein, we present a unique case of RAE diagnosed in a patient with primary APS who was well-managed on warfarin and rituximab with no recent thrombotic events. As RAE can precede or follow a diagnosis of APS, the presence of the condition indicates a need to workup for APS and to ensure those with the condition are adequately anticoagulated. However, as demonstrated in this case, the condition can still occur in patients who are adequately anticoagulated.

    Topics: Anticoagulants; Antiphospholipid Syndrome; Hemangioendothelioma; Humans; Male; Middle Aged; Rituximab; Skin Neoplasms; Warfarin

2021